Business
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy 
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to dat...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy \nAt week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36. Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events (\"SAEs\"), and no cases of oral candidiasis. VICTORIA, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (\"EoE\"). \"These tissue health data provide compelling evidence supporting our belief that EP-104GI is addressing the underlying pathology of EoE at the tissue level, as well as managing symptoms,\" said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. \"While early, the EoEHSS improvements we're seeing are encouraging - particularly at the highest dose where patients are achieving near-complete normalization of tissue health. What's especially encouraging is the improvement in tissue health is being accompanied by improvements in symptom relief. These improvements are maintained out to 52 weeks after a single administration with no serious adverse events, reinforcing EP-104GI's potential to significantly improve upon the current standard of care as a once-yearly treatment.\" Key New Findings from the RESOLVE Trial Tissue Health Outcomes At 12 weeks after administration, patients who received the highest dose level of EP-104GI (Cohort 9, 8mg/site, 20 sites, n=3), demonstrated the greatest improvement from ...